Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Asrih, Mohamed ^a   MacH, François ^a   Nencioni, Alessio ^b   Dallegri, Franco ^b   Quercioli, Alessandra ^a   Montecucco, Fabrizio ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SIZE; HEART VENTRICLE WALL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UPREGULATION; ANIMAL; CARDIOMEGALY; ENZYMOLOGY; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; HUMANS; METABOLIC SYNDROME X; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84873353766     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/367245     Document Type: Review

References (111)

1. Isomaa B., Almgren P., Tuomi T., Forsén B., Lahti K., Nissén M., Taskinen M. R., Groop L., Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 24 4 683 689 2-s2.0-0034837376 (Pubitemid 32893993)
2. Eckel R. H., Grundy S. M., Zimmet P. Z., The metabolic syndrome. The Lancet 2005 365 9468 1415 1428 2-s2.0-17144380822 10.1016/S0140-6736(05)66378-7 (Pubitemid 40523737)
3. Armitage J. A., Khan I. Y., Taylor P. D., Nathanielsz P. W., Poston L., Developmental programming of the metabolic syndrome by maternal nutritional imbalance: how strong is the evidence from experimental models in mammals? Journal of Physiology 2004 561 2 355 377 2-s2.0-10644263218 10.1113/jphysiol. 2004.072009 (Pubitemid 39646527)
4. Montecucco F., Mach F., Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. Diabetes, Obesity and Metabolism 2009 11 5 445 454 2-s2.0-65449148280 10.1111/j.1463-1326.2008.00986.x
5. von Bibra H., St John Sutton M., Impact of diabetes on postinfarction heart failure and left ventricular remodeling. Current Heart Failure Reports 2011 8 242 251
6. Roden M., Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nature Clinical Practice Endocrinology and Metabolism 2006 2 6 335 348 2-s2.0-33745107554 10.1038/ncpendmet0190 (Pubitemid 43885913)
7. Lopaschuk G. D., Metabolic abnormalities in the diabetic heart. Heart Failure Reviews 2002 7 2 149 159 2-s2.0-0036278903 10.1023/A:1015328625394 (Pubitemid 34624803)
8. Szczepaniak L. S., Dobbins R. L., Metzger G. J., Sartoni-D'Ambrosia G., Arbique D., Vongpatanasin W., Unger R., Victor R. G., Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magnetic Resonance in Medicine 2003 49 3 417 423 2-s2.0-0037371754 10.1002/mrm.10372 (Pubitemid 36262808)
9. Buckberg G., Hoffman J. I. E., Mahajan A., Saleh S., Coghlan C., Cardiac mechanics revisited: the relationship of cardiac architecture to ventricular function. Circulation 2008 118 24 2571 2587 2-s2.0-58149376278 10.1161/CIRCULATIONAHA.107.754424
10. Zhang Y., Dong C., Regulatory mechanisms of mitogen-activated kinase signaling. Cellular and Molecular Life Sciences 2007 64 21 2771 2789 2-s2.0-38149085101 10.1007/s00018-007-7012-3 (Pubitemid 351152255)
11. Zhang W., Liu H. T., MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Research 2002 12 1 9 18 2-s2.0-0347997608 (Pubitemid 135708299)
12. Hefti M. A., Harder B. A., Eppenberger H. M., Schaub M. C., Signaling pathways in cardiac myocyte hypertrophy. Journal of Molecular and Cellular Cardiology 1997 29 11 2873 2892 2-s2.0-0031282191 10.1006/jmcc.1997.0523 (Pubitemid 27510755)
13. Peterson L. R., Waggoner A. D., Schechtman K. B., Meyer T., Gropler R. J., Barzilai B., Dávila-Román V. G., Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. Journal of the American College of Cardiology 2004 43 8 1399 1404 2-s2.0-1942420839 10.1016/j.jacc.2003.10.062 (Pubitemid 38496345)
14. Iacobellis G., Ribaudo M. C., Leto G., Zappaterreno A., Vecci E., Di Mario U., Leonetti F., Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity. Obesity Research 2002 10 8 767 773 2-s2.0-0036688964 (Pubitemid 135687517)
15. Wong C. Y., O'Moore-Sullivan T., Leano R., Byrne N., Beller E., Marwick T. H., Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004 110 19 3081 3087 2-s2.0-8544283794 10.1161/01.CIR.0000147184.13872.0F (Pubitemid 39492002)
16. Avelar E., Cloward T. V., Walker J. M., Farney R. J., Strong M., Pendleton R. C., Segerson N., Adams T. D., Gress R. E., Hunt S. C., Litwin S. E., Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension 2007 49 1 34 39 2-s2.0-33847622008 10.1161/01.HYP.0000251711.92482.14 (Pubitemid 46360338)
17. Kortelainen M. L., Myocardial infarction and coronary pathology in severely obese people examined at autopsy. International Journal of Obesity 2002 26 1 73 79 2-s2.0-0036154182 10.1038/sj/ijo/0801852 (Pubitemid 34098672)
18. Cummings P. M., Le B. H., Lopes M. B. S., Postmortem findings in morbidly obese individuals dying after gastric bypass procedures. Human Pathology 2007 38 4 593 597 2-s2.0-33947187211 10.1016/j.humpath.2006.09.021 (Pubitemid 46399886)
19. de Simone G., Palmieri V., Bella J. N., Celentano A., Hong Y., Oberman A., Kitzman D. W., Hopkins P. N., Arnett D. K., Devereux R. B., Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. Journal of Hypertension 2002 20 2 323 331 2-s2.0-0036464178 10.1097/00004872- 200202000-00024 (Pubitemid 34913799)
20. Fuentes L. D. L., Brown A. L., Mathews S. J., Waggoner A. D., Soto P. F., Gropler R. J., Dávila-Román V. G., Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. European Heart Journal 2007 28 5 553 559 2-s2.0-34250866507 10.1093/eurheartj/ehl526 (Pubitemid 47355514)
21. Azevedo A., Bettencourt P., Almeida P. B., Santos A. C., Abreu-Lima C., Hense H. W., Barros H., Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities-cross-sectional study of the general population. BMC Cardiovascular Disorders 2007 7, article 17 2-s2.0-34347376145 10.1186/1471-2261-7-17 (Pubitemid 47018656)
22. Meléndez G. C., McLarty J. L., Levick S. P., Du Y., Janicki J. S., Brower G. L., Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010 56 2 225 231 2-s2.0-77955500182 10.1161/HYPERTENSIONAHA.109.148635
23. Lopez-Andres N., Rousseau A., Akhtar R., Calvier L., Inigo C., Labat C., Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension 2012 60 563 573
24. Grundy S. M., Brewer H. B., Cleeman J. I., Smith S. C., Lenfant C., Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004 109 3 433 438 2-s2.0-0842277242 10.1161/01.CIR.0000111245.75752.C6 (Pubitemid 38133916)
25. Hannan R. D., Jenkins A., Jenkins A. K., Brandenburger Y., Cardiac hypertrophy: a matter of translation. Clinical and Experimental Pharmacology and Physiology 2003 30 8 517 527 2-s2.0-0041426310 10.1046/j.1440-1681.2003.03873.x (Pubitemid 37011588)
26. Peterson K. L., Pressure overload hypertrophy and congestive heart failure: where is the "Achilles' Heel"? Journal of the American College of Cardiology 2002 39 4 672 675 2-s2.0-0037138555 10.1016/S0735-1097(01) 01790-9 (Pubitemid 34158164)
27. Heckbert S. R., Post W., Pearson G. D. N., Arnett D. K., Gomes A. S., Jerosch-Herold M., Hundley W. G., Lima J. A., Bluemke D. A., Traditional Cardiovascular Risk Factors in Relation to Left Ventricular Mass, Volume, and Systolic Function by Cardiac Magnetic Resonance Imaging. The Multiethnic Study of Atherosclerosis. Journal of the American College of Cardiology 2006 48 11 2285 2292 2-s2.0-33845225600 10.1016/j.jacc.2006.03.072 (Pubitemid 44855426)
28. Iacobellis G., Ribaudo M. C., Zappaterreno A., Iannucci C. V., Di Mario U., Leonetti F., Adapted changes in left ventricular structure and function in severe uncomplicated obesity. Obesity Research 2004 12 10 1616 1621 2-s2.0-16644391590 (Pubitemid 41132470)
29. Tandri H., Castillo E., Ferrari V. A., Nasir K., Dalal D., Bomma C., Calkins H., Bluemke D. A., Magnetic resonance imaging of arrhythmogenic right ventricular dysplasia. Sensitivity, specificity, and observer variability of fat detection versus functional analysis of the right ventricle. Journal of the American College of Cardiology 2006 48 11 2277 2284 2-s2.0-33845219364 10.1016/j.jacc.2006.07.051 (Pubitemid 44855415)
30. Tansey D. K., Aly Z., Sheppard M. N., Fat in the right ventricle of the normal heart. Histopathology 2005 46 1 98 104 2-s2.0-13244276345 10.1111/j.1365-2559.2005.02054.x (Pubitemid 40193704)
31. Kim E., Choe Y. H., Han B. K., Kim S. M., Kim J. S., Park S. W., Sung J., Right ventricular fat infiltration in asymptomatic subjects: observations from ECG-gated 16-slice multidetector CT. Journal of Computer Assisted Tomography 2007 31 1 22 28 2-s2.0-33846575134 10.1097/01.rct.0000236416.05267.6c (Pubitemid 46183338)
32. Mazumder P. K., O'Neill B. T., Roberts M. W., Buchanan J., Yun U. J., Cooksey R. C., Boudina S., Abel E. D., Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004 53 9 2366 2374 2-s2.0-4344601004 10.2337/diabetes.53.9.2366 (Pubitemid 39145591)
33. Buchanan J., Mazumder P. K., Hu P., Chakrabarti G., Roberts M. W., Ui J. Y., Cooksey R. C., Litwin S. E., Abel E. D., Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005 146 12 5341 5349 2-s2.0-27844457564 10.1210/en.2005-0938 (Pubitemid 41653047)
34. Landau D., Chayat C., Zucker N., Golomb E., Yagil C., Yagil Y., Segev Y., Early blood pressure-independent cardiac changes in diabetic rats. Journal of Endocrinology 2008 197 1 75 83 2-s2.0-42449122727 10.1677/JOE-08-0040 (Pubitemid 351566927)
35. Bollano E., Omerovic E., Svensson H., Waagstein F., Fu M., Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats. International Journal of Cardiology 2007 114 2 195 201 2-s2.0-33751255379 10.1016/j.ijcard.2006.01.027 (Pubitemid 44791509)
36. Assmann G., Dyslipidaemia and global cardiovascular risk: clinical issues. European Heart Journal, Supplement 2006 8 F40 F46 2-s2.0-33749033623 10.1093/eurheartj/sul040 (Pubitemid 44453615)
37. Barylski M., Ciecwierz J., Banach M., Irzmanski R., Pawlicki L., Kowalski J., Left ventricular diastolic dysfunction in subjects with metabolic syndrome. Atherosclerosis Supplements 2008 9, article 232
38. Penjaskovic D., Sakac D., Dejanovic J., Zec R., Zec Petkovic N., Stojsic Milosavljevic A., Left ventricular diastolic dysfunction in patients with metabolic syndrome. Medicinski Pregled 2012 65 18 22
39. Mulè G., Nardi E., Cottone S., Cusimano P., Volpe V., Piazza G., Mongiovì R., Mezzatesta G., Andronico G., Cerasola G., Influence of metabolic syndrome on hypertension-related target organ damage. Journal of Internal Medicine 2005 257 6 503 513 2-s2.0-20144380553 10.1111/j.1365-2796. 2005.01493.x (Pubitemid 40776510)
40. Chinali M., Devereux R. B., Howard B. V., Roman M. J., Bella J. N., Liu J. E., Resnick H. E., Lee E. T., Best L. G., de Simone G., Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). American Journal of Cardiology 2004 93 1 40 44 2-s2.0-9144255550 10.1016/j.amjcard.2003.09.009 (Pubitemid 38028620)
41. Okin P. M., Devereux R. B., Jern S., Kjeldsen S. E., Julius S., Nieminen M. S., Snapinn S., Harris K. E., Aurup P., Edelman J. M., Wedel H., Lindholm L. H., Dahlöf B., Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. Journal of the American Medical Association 2004 292 19 2343 2349 2-s2.0-8544223585 10.1001/jama.292.19.2343 (Pubitemid 39491918)
42. Schillaci G., Pirro M., Vaudo G., Mannarino M. R., Savarese G., Pucci G., Franklin S. S., Mannarino E., Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005 45 6 1078 1082 2-s2.0-20044377422 10.1161/01.HYP.0000165313.84007.7d (Pubitemid 40770308)
43. Krauser D. G., Devereux R. B., Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz Kardiovaskuläre Erkrankungen 2006 31 4 305 316 2-s2.0-33745920519 10.1007/s00059-006-2819-5 (Pubitemid 44046493)
44. de Simone G., Devereux R. B., Chinali M., Roman M. J., Lee E. T., Resnick H. E., Howard B. V., Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. Nutrition, Metabolism and Cardiovascular Diseases 2009 19 7 520 2-s2.0-67651005598 10.1016/j.numecd.2009.03.009
45. Li Z. L., Woollard J. R., Ebrahimi B., Crane J. A., Jordan K. L., Lerman A., Transition from obesity to metabolic syndrome is associated with altered myocardial autophagy and apoptosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 1132 1141
46. Swynghedauw B., Molecular mechanisms of myocardial remodeling. Physiological Reviews 1999 79 1 215 262 2-s2.0-0032949682 (Pubitemid 29056953)
47. Zhu X. Y., Daghini E., Rodriguez-Porcel M., Chade A. R., Napoli C., Lerman A., Lerman L. O., Redox-sensitive myocardial remodeling and dysfunction in swine diet-induced experimental hypercholesterolemia. Atherosclerosis 2007 193 1 62 69 2-s2.0-34248661541 10.1016/j.atherosclerosis.2006.08.035 (Pubitemid 46776711)
48. Abel E. D., Litwin S. E., Sweeney G., Cardiac remodeling in obesity. Physiological Reviews 2008 88 2 389 419 2-s2.0-42049109696 10.1152/physrev. 00017.2007 (Pubitemid 351520084)
49. Meigs J. B., Rutter M. K., Sullivan L. M., Fox C. S., D'Agostino R. B., Wilson P. W. F., Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007 30 5 1219 1225 2-s2.0-34247603049 10.2337/dc06-2484 (Pubitemid 46684651)
50. Weber K. T., Brilla C. G., Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991 83 6 1849 1865 2-s2.0-0025770664
51. Sato A., Saruta T., Aldosterone escape during angiostensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. Journal of International Medical Research 2001 29 1 13 21 2-s2.0-0034745049 (Pubitemid 32236891)
52. Struthers A. D., The clinical implications of aldosterone escape in congestive heart failure. European Journal of Heart Failure 2004 6 5 539 545 2-s2.0-4043184149 10.1016/j.ejheart.2004.04.013 (Pubitemid 39070505)
53. Kosmala W., Przewlocka-Kosmala M., Szczepanik-Osadnik H., Mysiak A., O'Moore-Sullivan T., Marwick T. H., A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. Cardiovascular Imaging 2011 4 1239 1249
54. Opie L. H., Commerford P. J., Gersh B. J., Pfeffer M. A., Controversies in ventricular remodelling. The Lancet 2006 367 9507 356 367 2-s2.0-31444448021 10.1016/S0140-6736(06)68074-4 (Pubitemid 43151469)
55. Gallagher E. J., Leroith D., Karnieli E., Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mount Sinai Journal of Medicine 2010 77 5 511 523 2-s2.0-78449244718 10.1002/msj.20212
56. Lin H. V., Accili D., Hormonal regulation of hepatic glucose production in health and disease. Cell Metabolism 2011 14 1 9 19 2-s2.0-79959962745 10.1016/j.cmet.2011.06.003
57. Bochud M., Nussberger J., Bovet P., Maillard M. R., Elston R. C., Paccaud F., Shamlaye C., Burnier M., Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006 48 2 239 245 2-s2.0-33748141662 10.1161/01.HYP.0000231338.41548.fc (Pubitemid 44309818)
58. Calhoun D. A., Sharma K., The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiology Clinics 2010 28 3 517 527 2-s2.0-77954465954 10.1016/j.ccl.2010.04.001
59. El-Gharbawy A. H., Nadig V. S., Morley Kotchen J., Grim C. E., Sagar K. B., Kaldunski M., Hamet P., Pausova Z., Gaudet D., Gossard F., Kotchen T. A., Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001 37 3 845 850 2-s2.0-0035108054 (Pubitemid 32221602)
60. Brilla C. G., Matsubara L. S., Weber K. T., Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. Journal of Molecular and Cellular Cardiology 1993 25 5 563 575 2-s2.0-0027227646 10.1006/jmcc.1993.1066 (Pubitemid 23208145)
61. Matsumura K., Fujii K., Oniki H., Oka M., Iida M., Role of aldosterone in left ventricular hypertrophy in hypertension. American Journal of Hypertension 2006 19 1 13 18 2-s2.0-32344443557 10.1016/j.amjhyper.2005.05.013 (Pubitemid 43217027)
62. Okoshi M. P., Yan X., Okoshi K., Nakayama M., Schuldt A. J. T., O'Connell T. D., Simpson P. C., Lorell B. H., Aldosterone directly stimulates cardiac myocyte hypertrophy. Journal of Cardiac Failure 2004 10 6 511 518 2-s2.0-10344265494 10.1016/j.cardfail.2004.03.002
63. Yue T. L., Gu J. L., Wang C., Reith A. D., Lee J. C., Mirabile R. C., Kreutz R., Wang Y., Maleeff B., Parsons A. A., Ohlstein E. H., Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. Journal of Biological Chemistry 2000 275 48 37895 37901 2-s2.0-0034535088 10.1074/jbc.M007037200 (Pubitemid 32004908)
64. Wang L., Proud C. G., Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circulation Research 2002 91 9 821 829 2-s2.0-0036842351 10.1161/01.RES.0000041029.97988.E9 (Pubitemid 35285080)
65. Robert V., Van Thiem N., Cheav S. L., Mouas C., Swynghedauw B., Delcayre C., Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994 24 1 30 36 2-s2.0-0028360454 (Pubitemid 24195401)
66. Young M., Fullerton M., Dilley R., Funder J., Mineralocorticoids, hypertension, and cardiac fibrosis. Journal of Clinical Investigation 1994 93 6 2578 2583 2-s2.0-0028290539 (Pubitemid 24177174)
67. Sowers J. R., Metabolic risk factors and renal disease. Kidney International 2007 71 8 719 720 2-s2.0-34247264495 10.1038/sj.ki.5002006 (Pubitemid 46624014)
68. Sowers J. R., Whaley-Connell A., Epstein M., Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Annals of Internal Medicine 2009 150 11 776 783 2-s2.0-66549130863
69. Emanuela F., Grazia M., Marco de R., Maria Paola L., Giorgio F., Marco B., Inflammation as a link between obesity and metabolic syndrome. Journal of Nutrition and Metabolism 2012 2012 476380
70. Sartipy P., Loskutoff D. J., Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2003 100 12 7265 7270 2-s2.0-0038809142 10.1073/pnas.1133870100 (Pubitemid 36706427)
71. Wellen K. E., Hotamisligil G. S., Inflammation, stress, and diabetes. Journal of Clinical Investigation 2005 115 5 1111 1119 2-s2.0-18244370762 10.1172/JCI200525102 (Pubitemid 40629025)
72. Hotamisligil G. S., Shargill N. S., Spiegelman B. M., Adipose expression of tumor necrosis factor- α: direct role in obesity-linked insulin resistance. Science 1993 259 5091 87 91 2-s2.0-0027459878 (Pubitemid 23036092)
73. Shoelson S. E., Lee J., Goldfine A. B., Inflammation and insulin resistance. Journal of Clinical Investigation 2006 116 7 1793 1801 2-s2.0-33745861300 10.1172/JCI29069
74. Sack M. N., Smith R. M., Opie L. H., Tumor necrosis factor in myocardial hypertrophy and ischaemia-an anti-apoptotic perspective. Cardiovascular Research 2000 45 3 688 695 2-s2.0-0033980351 10.1016/S0008-6363(99)00228-X (Pubitemid 30047135)
75. Kapadia S. R., Oral H., Lee J., Nakano M., Taffet G. E., Mann D. L., Hemodynamic regulation of tumor necrosis factor- α gene and protein expression in adult feline myocardium. Circulation Research 1997 81 2 187 195 2-s2.0-0030794617 (Pubitemid 27342485)
76. Nakamura K., Fushimi K., Kouchi H., Mihara K., Miyazaki M., Ohe T., Namba M., Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor- α and angiotensin II. Circulation 1998 98 8 794 799 2-s2.0-0032566405 (Pubitemid 28391845)
77. Widmann C., Gibson S., Jarpe M. B., Johnson G. L., Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiological Reviews 1999 79 1 143 180 2-s2.0-0032928614 (Pubitemid 29056951)
78. Heineke J., Molkentin J. D., Regulation of cardiac hypertrophy by intracellular signalling pathways. Nature Reviews Molecular Cell Biology 2006 7 8 589 600 2-s2.0-33748323383 10.1038/nrm1983 (Pubitemid 44325350)
79. Takeishi Y., Huang Q., Abe J. I., Glassman M., Che W., Lee J. D., Kawakatsu H., Lawrence E. G., Hoit B. D., Berk B. C., Walsh R. A., Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch. Journal of Molecular and Cellular Cardiology 2001 33 9 1637 1648 2-s2.0-17944379672 10.1006/jmcc.2001.1427 (Pubitemid 32844222)
80. Esposito G., Perrino C., Schiattarella G. G., Belardo L., Di Pietro E., Franzone A., Capretti G., Gargiulo G., Pironti G., Cannavo A., Sannino A., Izzo R., Chiariello M., Induction of mitogen-activated protein kinases is proportional to the amount of pressure overload. Hypertension 2010 55 1 137 143 2-s2.0-73849151773 10.1161/HYPERTENSIONAHA.109.135467
81. Haq S., Choukroun G., Lim H., Tymitz K. M., Del Monte F., Gwathmey J., Grazette L., Michael A., Hajjar R., Force T., Molkentin J. D., Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001 103 5 670 677 2-s2.0-0035814747 (Pubitemid 32144195)
82. Rose B. A., Force T., Wang Y., Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiological Reviews 2010 90 4 1507 1546 2-s2.0-78149478401 10.1152/physrev.00054.2009
83. Babu G. J., Lalli J. M., Sussman M. A., Sadoshima J. I., Periasamy M., Phosphorylation of Elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy. Journal of Molecular and Cellular Cardiology 2000 32 8 1447 1457 2-s2.0-0033852655 10.1006/jmcc.2000.1185
84. Wang Y., Su B., Sah V. P., Brown J. H., Han J., Chien K. R., Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. Journal of Biological Chemistry 1998 273 20 5423 5426 2-s2.0-0032524642 (Pubitemid 28124000)
85. Bogoyevitch M. A., Gillespie-Brown J., Ketterman A. J., Fuller S. J., Ben-Levy R., Ashworth A., Marshall C. J., Sugden P. H., Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart: p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circulation Research 1996 79 2 162 173 2-s2.0-0030036727 (Pubitemid 26255867)
86. Petrich B. G., Eloff B. C., Lerner D. L., Kovacs A., Saffitz J. E., Rosenbaum D. S., Wang Y., Targeted activation of c-Jun N-terminal kinase in vivo induces restrictive cardiomyopathy and conduction defects. Journal of Biological Chemistry 2004 279 15 15330 15338 2-s2.0-2442575047 10.1074/jbc.M314142200 (Pubitemid 38618931)
87. Frantz S., Behr T., Hu K., Fraccarollo D., Strotmann J., Goldberg E., Ertl G., Angermann C. E., Bauersachs J., Role of p38 mitogen-activated protein kinase in cardiac remodelling. British Journal of Pharmacology 2007 150 2 130 135 2-s2.0-33846487259 10.1038/sj.bjp.0706963 (Pubitemid 46160602)
88. Ono K., Han J., The p38 signal transduction pathway Activation and function. Cellular Signalling 2000 12 1 1 13 2-s2.0-0033965158 10.1016/S0898-6568(99)00071-6 (Pubitemid 30017963)
89. Waehre A., Halvorsen B., Yndestad A., Husberg C., Sjaastad I., Nygård S., Dahl C. P., Ahmed M. S., Finsen A. V., Reims H., Louch W. E., Hilfiker-Kleiner D., Vinge L. E., Roald B., Attramadal H., Lipp M., Gullestad L., Aukrust P., Christensen G., Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload. PLoS ONE 2011 6 4 2-s2.0-79955147985 10.1371/journal.pone. 0018668 e18668
90. Lacerda-Miranda G., Soares V. M., Vieira A. K. G., Lessa J. G., Rodrigues-Cunha A. C. S., Cortez E., Ghrelin signaling in heart remodeling of adult obese mice. Peptides 2012 35 65 73
91. Besnard A., Galan-Rodriguez B., Vanhoutte P., Caboche J., Elk-1 a transcription factor with multiple facets in the brain. Frontiers in Neuroscience 2011 5, article 35
92. Darragh J., Soloaga A., Beardmore V. A., Wingate A. D., Wiggin G. R., Reggie M., Arthur J. S. C., MSKs are required for the transcription of the nuclear orphan receptors Nur77, Nurr1 and Nor1 downstream of MAPK signalling. Biochemical Journal 2005 390 3 749 759 2-s2.0-25844444745 10.1042/BJ20050196 (Pubitemid 41395358)
93. Han J., Molkentin J. D., Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. Trends in Cardiovascular Medicine 2000 10 1 19 22 2-s2.0-0034528548 10.1016/S1050-1738(00)00039-6 (Pubitemid 32012677)
94. Liang Q., Molkentin J. D., Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. Journal of Molecular and Cellular Cardiology 2003 35 12 1385 1394 2-s2.0-0344924887 10.1016/j.yjmcc.2003.10.001 (Pubitemid 37491181)
95. Nemoto S., Sheng Z., Lin A., Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Molecular and Cellular Biology 1998 18 6 3518 3526 2-s2.0-0031844392 (Pubitemid 28240524)
96. Zechner D., Thuerauf D. J., Hanford D. S., McDonough P. M., Glembotski C. C., A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. Journal of Cell Biology 1997 139 1 115 127 2-s2.0-0030749330 10.1083/jcb.139.1.115 (Pubitemid 27444085)
97. Chen L. M., Kuo W. W., Yang J. J., Wang S. G. P., Yeh Y. L., Tsai F. J., Ho Y. J., Chang M. H., Huang C. Y., Lee S. D., Eccentric cardiac hypertrophy was induced by long-term intermittent hypoxia in rats. Experimental Physiology 2007 92 2 409 416 2-s2.0-33847766236 10.1113/expphysiol.2006.036590 (Pubitemid 46376327)
98. Choukroun G., Hajjar R., Kyriakis J. M., Bonventre J. V., Rosenzweig A., Force T., Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. Journal of Clinical Investigation 1998 102 7 1311 1320 2-s2.0-0032190461 (Pubitemid 28467559)
99. Liao P., Georgakopoulos D., Kovacs A., Zheng M., Lerner D., Pu H., Saffitz J., Chien K., Xiao R. P., Kass D. A., Wang Y., The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America 2001 98 21 12283 12288 2-s2.0-0035834071 10.1073/pnas.211086598 (Pubitemid 32959865)
100. Montecucco F., Steffens S., Mach F., Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators of Inflammation 2008 2008 2-s2.0-47349099600 10.1155/2008/767623 767623 (Pubitemid 352000410)
101. Wang Y., Mitogen-activated protein kinases in heart development and diseases. Circulation 2007 116 12 1413 1423 2-s2.0-34548695952 10.1161/CIRCULATIONAHA.106.679589 (Pubitemid 47417568)
102. Satoh Y., Endo S., Ikeda T., Yamada K., Ito M., Kuroki M., Hiramoto T., Imamura O., Kobayashi Y., Watanabe Y., Itohara S., Takishima K., Extracellular signal-regulated kinase 2 (ERK2) knockdown mice show deficits in long-term memory; ERK2 has a specific function in learning and memory. Journal of Neuroscience 2007 27 40 10765 10776 2-s2.0-35148894535 10.1523/JNEUROSCI.0117- 07.2007 (Pubitemid 47535863)
103. Bélanger L. F., Roy S., Tremblay M., Brott B., Steff A. M., Mourad W., Hugo P., Erikson R., Charron J., MEK2 is dispensable for mouse growth and development. Molecular and Cellular Biology 2003 23 14 4778 4787 2-s2.0-1242290740 10.1128/MCB.23.14.4778-4787.2003 (Pubitemid 36793325)
104. Bost F., Aouadi M., Caron L., Even P., Belmonte N., Prot M., Dani C., Hofman P., Pagès G., Pouysségur J., Le Marchand-Brustel Y., Binétruy B., The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis. Diabetes 2005 54 2 402 411 2-s2.0-19944433322 10.2337/diabetes.54.2.402
105. Lee S. J., Pfluger P. T., Kim J. Y., Nogueiras R., Duran A., Pagès G., Pouysségur J., Tschöp M. H., Diaz-Meco M. T., Moscat J., A functional role for the p62-ERK1 axis in the control of energy homeostasis and adipogenesis. EMBO Reports 2010 11 3 226 232 2-s2.0-77649265416 10.1038/embor.2010.7
106. Monteiro R., Azevedo I., Chronic inflammation in obesity and the metabolic syndrome. Mediators of Inflammation 2010 2010 2-s2.0-77955362775 10.1155/2010/289645 289645
107. Condorelli G., Morisco C., Latronico M. V. G., Claudio P. P., Dent P., Tsichlis P., Condorelli G., Frati G., Drusco A., Croce C. M., Napoli C., TNF- α signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF- α receptor. FASEB Journal 2002 16 13 1732 1737 2-s2.0-18744374674 10.1096/fj.02-0419com (Pubitemid 35340353)
108. Hirota H., Yoshida K., Kishimoto T., Taga T., Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proceedings of the National Academy of Sciences of the United States of America 1995 92 11 4862 4866 2-s2.0-0028997843 10.1073/pnas.92.11.4862
109. Moreno-Aliaga M. J., Perez-Echarri N., Marcos-Gomez B., Larequi E., Gil-Bea F. J., Viollet B., Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metabolism 2011 14 242 253
110. Natal C., Fortuño M. A., Restituto P., Bazán A., Colina I., Díez J., Varo N., Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. American Journal of Physiology 2008 294 1 E52 E60 2-s2.0-38349016317 10.1152/ajpendo.00506.2007
111. Thandavarayan R. A., Watanabe K., Ma M., Gurusamy N., Veeraveedu P. T., Konishi T., Zhang S., Muslin A. J., Kodama M., Aizawa Y., Dominant-negative p38 α mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. American Journal of Physiology 2009 297 3 H911 H919 2-s2.0-69249100552 10.1152/ajpheart.00124.2009